Key facts
- It has raised $6.8M; the latest was Accelerator/Incubator in Feb 2025.
- Notable investors include National Institutes of Health, Joyance Partners, One Mind, Prime Movers Lab, Satori Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Attune Neurosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Attune Neurosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Attune Neurosciences
Developer of neurostimulation products designed to improve human health and performance. The company's products target sleep-related conditions that modulate the activity of the brain structures, enabling patients to improve symptoms of central nervous system disorders for patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 22
- Website
- attuneneuro.com/
- Ownership
- Privately Held (backing)
Attune Neurosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Attune Neurosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Attune Neurosciences in its N-PORT filings yet. We sweep new filings monthly.